CSCI Valuation
COSCIENS Biopharma Inc
$
2.850
- Overview
- Forecast
- Valuation
- Earnings
CSCI Relative Valuation
CSCI's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, CSCI is overvalued; if below, it's undervalued.
Historical Valuation
COSCIENS Biopharma Inc (CSCI) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.76 is considered Undervalued compared with the five-year average of -3.15. The fair price of COSCIENS Biopharma Inc (CSCI) is between 5.60 to 11.69 according to relative valuation methord. Compared to the current price of 2.85 USD , COSCIENS Biopharma Inc is Undervalued By 49.12%.
Relative Value
Fair Zone
5.60-11.69
Current Price：2.85
49.12%
Undervalued
0.16
PE
1Y
3Y
5Y
Trailing
Forward
0.00
EV/EBITDA
COSCIENS Biopharma Inc. (CSCI) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is 0.08. The thresholds are as follows: Strongly Undervalued below -0.55, Undervalued between -0.55 and -0.23, Fairly Valued between 0.39 and -0.23, Overvalued between 0.39 and 0.71, and Strongly Overvalued above 0.71. The current Forward EV/EBITDA of 0.00 falls within the Historic Trend Line -Fairly Valued range.
-0.37
EV/EBIT
COSCIENS Biopharma Inc. (CSCI) has a current EV/EBIT of -0.37. The 5-year average EV/EBIT is -0.06. The thresholds are as follows: Strongly Undervalued below -7.88, Undervalued between -7.88 and -3.97, Fairly Valued between 3.85 and -3.97, Overvalued between 3.85 and 7.76, and Strongly Overvalued above 7.76. The current Forward EV/EBIT of -0.37 falls within the Historic Trend Line -Fairly Valued range.
0.76
PS
COSCIENS Biopharma Inc. (CSCI) has a current PS of 0.76. The 5-year average PS is 10.06. The thresholds are as follows: Strongly Undervalued below -20.20, Undervalued between -20.20 and -5.07, Fairly Valued between 25.18 and -5.07, Overvalued between 25.18 and 40.31, and Strongly Overvalued above 40.31. The current Forward PS of 0.76 falls within the Historic Trend Line -Fairly Valued range.
0.00
P/OCF
COSCIENS Biopharma Inc. (CSCI) has a current P/OCF of 0.00. The 5-year average P/OCF is -2.19. The thresholds are as follows: Strongly Undervalued below -10.98, Undervalued between -10.98 and -6.59, Fairly Valued between 2.20 and -6.59, Overvalued between 2.20 and 6.59, and Strongly Overvalued above 6.59. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.
0.00
P/FCF
COSCIENS Biopharma Inc. (CSCI) has a current P/FCF of 0.00. The 5-year average P/FCF is 0.10. The thresholds are as follows: Strongly Undervalued below -0.33, Undervalued between -0.33 and -0.12, Fairly Valued between 0.32 and -0.12, Overvalued between 0.32 and 0.53, and Strongly Overvalued above 0.53. The current Forward P/FCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.
COSCIENS Biopharma Inc (CSCI) has a current Price-to-Book (P/B) ratio of 0.88. Compared to its 3-year average P/B ratio of 0.55 , the current P/B ratio is approximately 61.59% higher. Relative to its 5-year average P/B ratio of 1.26, the current P/B ratio is about -30.09% higher. COSCIENS Biopharma Inc (CSCI) has a Forward Free Cash Flow (FCF) yield of approximately -144.85%. Compared to its 3-year average FCF yield of -147.93%, the current FCF yield is approximately -2.08% lower. Relative to its 5-year average FCF yield of -92.95% , the current FCF yield is about 55.85% lower.
0.88
P/B
Median3y
0.55
Median5y
1.26
-144.85
FCF Yield
Median3y
-147.93
Median5y
-92.95
Competitors Valuation Multiple
The average P/S ratio for CSCI's competitors is 2.99, providing a benchmark for relative valuation. COSCIENS Biopharma Inc Corp (CSCI) exhibits a P/S ratio of 0.76, which is -74.62% above the industry average. Given its robust revenue growth of 37400.00%, this premium appears sustainable.
Performance Decomposition
1Y
3Y
5Y
Market capitalization of CSCI decreased by 22.97% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 4.00K to 1.50M.
The secondary factor is the Margin Expansion, contributed -99.83%to the performance.
Overall, the performance of CSCI in the past 1 year is driven by Revenue Growth. Which is more sustainable.
People Also Watch
RDIB
Reading International Inc
11.810
USD
-10.53%
IVDA
Iveda Solutions Inc
1.700
USD
-6.59%
SGLY
Singularity Future Technology Ltd
0.950
USD
-1.45%
ASTC
Astrotech Corp
5.030
USD
-1.37%
MNDR
Mobile-health Network Solutions
1.091
USD
+1.96%
ADGM
Adagio Medical Holdings Inc
1.280
USD
+1.19%
YQ
17 Education & Technology Group Inc
1.964
USD
+0.72%
FAQ
Is COSCIENS Biopharma Inc (CSCI) currently overvalued or undervalued?
COSCIENS Biopharma Inc (CSCI) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.76 is considered Undervalued compared with the five-year average of -3.15. The fair price of COSCIENS Biopharma Inc (CSCI) is between 5.60 to 11.69 according to relative valuation methord. Compared to the current price of 2.85 USD , COSCIENS Biopharma Inc is Undervalued By 49.12% .
What is COSCIENS Biopharma Inc (CSCI) fair value?
How does CSCI's valuation metrics compare to the industry average?
What is the current P/B ratio for COSCIENS Biopharma Inc (CSCI) as of Aug 18 2025?
What is the current FCF Yield for COSCIENS Biopharma Inc (CSCI) as of Aug 18 2025?
What is the current Forward P/E ratio for COSCIENS Biopharma Inc (CSCI) as of Aug 18 2025?